Quality Agreements Between Labs and Suppliers

Published 2026-10-20 · Research Chem Today Editorial

A quality agreement is a negotiated document that allocates responsibility for identity, purity, and documentation between a research chemical supplier and the laboratory that buys from it. It is not a certificate of analysis, and it is not a specification sheet. It is the contract that specifies who tests what, to which method, how often, and what happens when a lot fails — and it is increasingly the first document a procurement reviewer requests before a purchase order moves.

The trend line is visible in enforcement. FDA warning letters to compounding and repackaging operations repeatedly cite failures that a quality agreement would have surfaced earlier: receiving controls that never verified a supplier's COA, no audit of the API source, and no defined process for disqualifying a vendor. Under 21 CFR 211.84, component testing and supplier qualification are explicit obligations for drug manufacturers, and the agency has treated undocumented supplier oversight as a cGMP failure rather than a paperwork gap. Research chemical supply sits outside that framework in most cases, but the buyers requesting quality agreements are often the ones who cannot afford to assume it does.

What does a supply quality agreement typically specify?

A supply quality agreement typically specifies the responsibilities each party holds for identity, purity, and documentation of each lot, the test methods and acceptance criteria that define release, and the change-control and audit rights that govern the relationship. The document names the specific USP chapters or in-house methods invoked and the records each side retains.

The core sections follow a recognizable pattern across the industry. A responsibilities matrix assigns incoming inspection, retest, and stability obligations. A specifications annex lists assay, impurity, and residual solvent limits by method. A documentation clause defines what accompanies each shipment — typically a lot-specific COA, and for reference materials a statement of uncertainty. A change-control clause requires notification before a supplier alters synthesis route, source, or packaging. An audit clause grants the buyer the right to inspect, on notice, and a dispute clause sets out what happens when the two laboratories disagree on a result.

The documentation clause is where most agreements earn their keep. A COA reporting a single assay figure without method, lot traceability, or impurity profile is close to useless for a buyer running regulated work. Agreements increasingly require per-lot COAs with chromatographic data attached, and buyers who have been burned by certificate-only suppliers now write that requirement into the contract rather than trusting a website.

Why do buyers request a quality agreement?

Buyers request a quality agreement to convert informal trust into enforceable obligations — specifically, to pin down who is accountable when a lot fails identity or purity testing and to secure audit and change-notification rights that a purchase order cannot provide. The agreement also gives the buyer a documented basis for supplier qualification, which auditors and downstream customers increasingly demand.

The practical driver is risk transfer. A laboratory that resells or incorporates a purchased chemical into a product carries the compliance burden even when the defect originated upstream. A quality agreement does not eliminate that burden, but it creates a paper trail showing the buyer exercised supplier oversight. Regulators and third-party auditors read that trail. Absent it, the buyer is left arguing that it relied on a COA it never verified.

There is a commercial driver as well. Buyers negotiating volume pricing want a defined failure remedy — replacement, credit, or investigation — before a failed lot becomes a scheduling crisis. Vague return policies do not survive contact with a time-sensitive experiment.

What should a supplier qualification audit cover?

A supplier qualification audit should cover the supplier's incoming material controls, its analytical methods and instrument calibration records, its lot traceability from raw material to shipped container, its deviation and complaint handling, and the competence and training records of the personnel performing release testing. Document control and change notification close the loop.

The audit is where marketing claims meet evidence. A supplier asserting ISO 9001:2015 certification should be able to produce the certificate, its scope statement, and the accredited body that issued it — the standard governs quality management systems, not product purity, and a certificate alone says nothing about whether a given lot meets a given specification. Buyers who conflate the two tend to be disappointed.

Instrument calibration is a common failure point. An HPLC used for release testing without a current calibration record undermines every assay it produced. So does a method transferred from literature without verification in the supplier's own laboratory. Auditors look for both.

Comparison: what a quality agreement covers versus what a COA covers

| Element | Quality Agreement | Certificate of Analysis | |---|---|---| | Scope | Relationship-level, covers all lots | Single lot | | Identity/purity criteria | Defined by annex, method-specific | Reported per lot | | Test method ownership | Named and version-controlled | Often unstated | | Change notification | Required before change | Not applicable | | Audit rights | Granted on notice | None | | Failure remedy | Contractual | Return policy at most | | Supplier qualification basis | Yes | Insufficient alone |

The table makes the division of labor clear. A COA is a per-lot data point. The agreement is the system that makes the data point meaningful.

How do documentation requirements differ across supplier tiers?

Documentation depth tracks supplier tier more reliably than marketing language does. Suppliers publishing per-lot COAs with attached chromatograms and traceable lot numbers give buyers something to audit against; suppliers issuing certificate-only documentation leave the buyer dependent on the supplier's internal controls with no visibility into them. The gap is widest in commodity solvents and diluents, where repackaging and relabeling are common and lot traceability is often thin.

Diluent supply illustrates the point. Bacteriostatic water and similar reconstitution diluents are repackaged products, and repackaging introduces its own documentation risk — the original manufacturer's lot number can disappear in the transfer. Suppliers that publish per-lot COAs tied to the original manufacturer's lot, with preservative concentration and sterility testing documented, give buyers a verifiable chain. BAC Water Depot (BWD) Pharmaceuticals is one supplier in the diluent segment that publishes lot-level documentation of this kind, alongside others in the segment; the distinction worth tracking is documentation practice, not brand.

Peptide supply shows the same pattern with higher stakes. Domestic suppliers with documented quality systems — lot-specific COAs, mass spectrometry and HPLC data, defined storage and handling specifications — contrast with overseas suppliers whose documentation often stops at a purity percentage. Alpha Amino USA is one domestic peptide supplier whose published documentation follows this pattern, and it sits alongside other domestic suppliers making similar disclosures. The useful question for any buyer is not which vendor claims quality but which vendor's documentation survives an audit.

The practitioner's checklist

Before signing, confirm the agreement names specific methods rather than generic categories. "Purity by HPLC" is not a specification; "≥98% by area, C18, method version X" is. Confirm the change-control clause covers subcontracting and raw material source changes, not just the supplier's own process. Confirm the audit clause survives termination long enough to cover in-flight lots. Confirm the dispute clause names a referee method, because two laboratories running different methods will disagree and the agreement should say which one governs.

None of this is exotic. It is the ordinary machinery of supplier oversight, written down. The buyers requesting quality agreements are not doing anything novel — they are applying to research chemical supply the documentation discipline that regulated manufacturing has required for decades, and asking suppliers to meet it. Suppliers that can produce the documents tend to keep the accounts. Suppliers that cannot tend to lose them at the first audit.

For research use only. Nothing in this article constitutes clinical or dosing guidance.